RxDoctor Payments DataLook up a doctor →

Franklin Ampadu, MD

Internal Medicine · Wilmington, DENPI 1245236843

Payments from drug & device makers

$15,118in general payments, 2019–2025

Across 914 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$993
  • Pfizer$959
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$15,081100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,118 in reported general payments places this provider in the 95th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$81,657
Medicare patients
237
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$106,497
JardianceEmpagliflozin49$55,997
JanuviaSitagliptin Phosphate45$54,692
EliquisApixaban56$51,740
XareltoRivaroxaban47$41,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$37,325
TradjentaLinagliptin31$26,361
MyrbetriqMirabegron20$18,370
JanumetSitagliptin Phos/Metformin Hcl20$17,053
VeozahFezolinetant15$8,757
Dexlansoprazole DrDexlansoprazole35$7,886
Atorvastatin Calcium542$6,686
LinzessLinaclotide12$6,519
SymbicortBudesonide/Formoterol Fumarate17$5,877
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$5,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,196$106,49793 claims
Boehringer IngelheimJardiance, Tradjenta$1,246$82,35880 claims
MerckJanuvia, Janumet$259$71,74565 claims
PfizerEliquis$959$51,74056 claims
Johnson & JohnsonXarelto$197$41,73647 claims
GSKTrelegy Ellipta$1,714$37,32546 claims
Astellas Pharma US IncMyrbetriq, Veozah$473$27,12735 claims
AbbVieLinzess$412$6,51912 claims
AstraZenecaSymbicort$2,093$5,87717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →